INDEX

Abbreviations, xi–xiii
Absolute risk reduction (ARR), 108
ACCULINK™ carotid stent system, 215, 217
ACCULINK™ for revascularization of carotids in high-risk patients (ARCHeR) clinical trials, 215–217
advantage of historic control in, 217
Action items, in interim monitoring visit report, 80
Acute myocardial infarction (AMI), 123–124. See also Myocardial infarction (MI)
Adaptive sample size approach, Bayesian statistics in, 109–110
Administrative information, in clinical protocol, 19
Adverse device effects, xvii
unanticipated, 150
Adverse event case report forms (AE-CRFs), in standard operating procedure, 60
Adverse event narratives, serious, 89–90
Adverse Event Recording case report forms, 87–88
Adverse-event reporting, 84–85

gaps/challenges in, 86–88
pathway of, 84–85
in postmarket studies, 91
special requirements for, 92
time periods for, 88
in the United States versus Europe, 88–89
Adverse events (AEs), xvi, 81–92. See also Adverse-event reporting;
Serious adverse events (SAEs);
Unanticipated adverse device effects (UADEs)
analysis of, 91
in clinical protocol, 20
defined, xvii–xviii, 83
device-related, 39
evaluation of, 82
in interim monitoring visit report, 75
interim monitoring visits and, 71
monitor duties and, 68
reporting of, 24
in standard operating procedure, 59, 60
types/classification of, 82–83, 90–91

Design, Execution, and Management of Medical Device Clinical Trials,
by Salah Abdel-aleem
Copyright © 2009 John Wiley & Sons, Inc.
Adverse Events protocol section, 24–25
Advertising materials, IRB/EC approval of, 5
Advisory panels, FDA, 138
α. See Choice of α and β; Type I/II errors
Alternative procedures, 36
AMIHOT I/II studies, 123–124
Amputation, randomizing versus, 210
Analysis of variance (ANOVA), 104
Angiotensin II Antagonist Trial, 204–205
Animals, dosing studies in, 167
Animal studies, 166–167
Annotated CRFs, 29
Anticipated adverse events, 83
recording, 87
in standard operating procedure, 59, 60
A posteriori hypotheses, 106
Appendixes, 154
A priori hypotheses, 106
ARCHeR 1 study, 215, 216, 217
ARCHeR 2 study, 215, 216, 217
ARCHeR 3 study, 215, 217
Australia, device approvals in, 152
Authorization requirement, waiver of, 178–179
Bare metal stent (BMS) controlled trial, 205
Baseline characteristics, in final clinical study report, 114–115
Baseline medical history, in CRFs, 34
Bayesian statistics, 109–110
Bayes’s theorem, 109
Belmont Report, xix, 232
Bench testing, 167
Benefit analysis, in clinical protocol, 20
Benefit maximization, in protocol development process, 19
Best-case historical control, 211
β. See Choice of α and β; Type I/II errors
Bias
in clinical trials, 107
in financial disclosure certificate, 52
in a study, 121
BIMO audit, 192. See also Bioresearch Monitoring Program (BIMO) regulatory/administrative follow-up of outcome of, 193
Biocompatibility testing, 167
Bioethics principles, xix
Biologic products, primary mode of action of, 165
Bioresearch monitoring, 191–194
Bioresearch Monitoring Program (BIMO), 191–194
Biostatistician, 12
Biostatistics, xvi, 101–112
Blinding, 202
in clinical protocol, 4
Blindness, 26
Blocking, 201
Bypass, randomizing versus, 210–211
Canada, device approvals in, 152
CAPRICORN trial, composite endpoints for, 100
Cardiac outcome measures, 108
Carotid Stent System Study, 215–217
Case report forms (CRFs), xvii, 7, 8, 16, 28–32, 154. See also Adverse event case report forms (AE-CRFs); CRF entries; Study case report forms (CRFs)
adverse events in, 31, 85, 87–88
Baseline Medical History section in
Baseline characteristics in, 114–115
Baseline medical history in, 34
Bayesian statistics in, 109–110
Bayes’s theorem in, 109
Belmont Report in, xix, 232
Bench testing in, 167
Benefit analysis in, clinical protocol, 20
Benefit maximization in, protocol development process, 19
Best-case historical control in, 211
β. See Choice of α and β; Type I/II errors
Bias in clinical trials, 107
in financial disclosure certificate, 52
in a study, 121
BIMO audit, 192. See also Bioresearch Monitoring Program (BIMO) regulatory/administrative follow-up of outcome of, 193
Biocompatibility testing, 167
Bioethics principles, xix
Biologic products, primary mode of action of, 165
Bioresearch monitoring, 191–194
Bioresearch Monitoring Program (BIMO), 191–194
Biostatistician, 12
Biostatistics, xvi, 101–112
Blinding, 202
in clinical protocol, 4
Blindness, 26
Blocking, 201
Bypass, randomizing versus, 210–211
Canada, device approvals in, 152
CAPRICORN trial, composite endpoints for, 100
Cardiac outcome measures, 108
Carotid Stent System Study, 215–217
Case report forms (CRFs), xvii, 7, 8, 16, 28–32, 154. See also Adverse event case report forms (AE-CRFs); CRF entries; Study case report forms (CRFs)
adverse events in, 31, 85, 87–88
Baseline Medical History section in, 34
challenges in writing, 36–37
completing and correcting, 30–32
demographics section in, 33
enrollment section in, 33
global clinical studies and, 163
interim monitoring visits and, 71, 79
Medication(s) Used section in, 34
monitor duties and, 69
in monitoring plan, 69
Physical Exam section in, 34
protocol deviations in, 31
screening and enrollment in, 31
sections of, 30–32
in standard operating procedure, 59, 60, 61
study close-out visit and, 72
study completion data in, 32
in trial site agreement, 46
Verification of Subject Eligibility section in, 34
Case report form template, example of, 32–34
Causality assessment, terms related to, 85
Causal pathways, surrogate endpoints and, 99
CDRH advisory committees, 138. See also Center for Devices and Radiological Health (CDRH)
Center for Devices and Radiological Health (CDRH)
combination products and, 164
product codes of, 137
responsibilities of, 131–133
on RX and OTW ACCULINK™ carotid stent systems, 217
Center for drug evaluation and research (CDER), combination products and, 164
Centers for Medicare and Medicaid Services (CMS) device categorization, 141
Central IRBs, 180
Certificates, 51–52
Certification, in device investigational plan, 155
Check boxes, in CRFs, 29
Chi-squared test, 105
Choice of \( \alpha \) and \( \beta \), 105
in sample-size calculation, 103, 104
type I/II errors and, 102
Class I devices, 132–133, 144
Class II devices, 133, 144
Class III devices, 133, 159
Clinical activities, study-visit-related, 70
Clinical Affairs (CA) department, in standard operating procedure, 56, 58
Clinical affairs management, in standard operating procedure, 59
Clinical center, in standard operating procedure, 56, 58
Clinical decision making, 107–109
Clinical deliverables, 2–3
in the IDE, 155–156
Clinical Event Adjudication Committees (CEC), 27
Clinical Events Committees (CECs), 169–170
adverse events and, 82
bias minimization and, 107
in medical device regulation, 129
setting up, 168
Clinical experts, in protocol development, 3
Clinical forms, xvii, 51–54. See also Case report forms (CRFs)
Clinical investigations, IRB review and approval of, 187
Clinical investigators, 154
inspection of, 191–192
Clinical materials, 40
development of, 15–62
Clinical outcomes, 108
surrogate endpoints and, 99
Clinical protocol, 17–28
adverse events and, 82
attachments to, 28
development of, 3–4, 17–18, 18–20
monitoring plan in, 69–70
outline of, 19–20
schedule of assessments in, 23–24
in standard operating procedure, 61
Clinical protocol amendment, in standard operating procedure, 61
Clinical protocol sections
Background and Rationale, 19, 21
Intended Use, 19, 21–22
Study Design, 19–20, 22–23
Study Purpose, 17, 19, 21
Clinical reports
final study, 8
study progress, 8–9
Clinical research
biostatistics in, 101–112
concerns on use of placebo in, 232–233
HIPAA privacy rule implementation in, 175–180
investigator-initiated, 221–233
monitoring, 183
NIH-sponsored, 227
statistical analysis plan in, 93–101
Clinical research associates (CRAs), 12
Clinical research bioethics, review of, xvi
Clinical Research Coordinator (CRC), in standard operating procedure, 56
Clinical Research Organization (CRO), in standard operating procedure, 56
Clinical research team, 10–13
Clinical site(s) monitoring visits to, 67–68
qualification and selection of, 4
in standard operating procedure, 56, 58
Clinical standard operating procedures (SOPs), xvii, 54–62. See also SOP entries rationale for developing, 55
Clinical statistics, versus clinical practice, 105–106
Clinical studies. See also Study entries
FDA acceptance of, xviii
foreign, 162
global, 162–164
with historic controls, 209–217
key clinical deliverables for, 2–3
qualification/selection of investigators for, 64–67
special requirements for, 66–67
Clinical study activities spread sheet, 10, 11
Clinical study designs, xvi, xviii differences in, 147–148
Clinical study endpoints, selecting, 97–101
Clinical study manager, 11–12
Clinical study reports, xvi, xviii final, 113–125
Clinical study tasks/activities, 1–13
Clinical study team, in standard operating procedure, 62
Clinical tasks/activities, management of, 2, 9–10, 11
Clinical team, 2
Clinical trial design, 167–168, 196
assumptions and parameters of, 196–202
issues related to, 202–206
Clinical trials changing the primary outcome during, 101
characteristics of SAP for, 96–97
composite endpoints for, 100
FDA oversight of, 191–194
good clinical practice in, 157–158
international regulation of, xvi
investigator-initiated, xvi
investigator-sponsored, xix
minimization of bias in, 107
preparation of, 16–17
registration of, 174
requirements for, xv
ClinicalTrials.gov, 174
Clinical trial site agreement, example of, 43–50. See also Trial site agreement
Clinical trial tasks, xvi–xvii
diversity of, xv
overview of, xv
Code of Federal Regulations (CFR), 35–36, 84
medical devices and, 194
in standard operating procedure, 57, 61, 62
in trial site agreement, 44
Combination products, 164–168
jurisdictional determination of, 164–165
key information resources for, 168
regulations regarding, xviii
Committees, in clinical protocol, 4
Compassionate use, of unapproved medical devices, 160–162
Complete cases analysis of, 121–121
in a study, 121
Compliance analysis, in the final clinical study report, 120–121
Compliance assessment, interim monitoring visits and, 71
Compliance classifications, of the BIMO audit, 192
Composite endpoints, 100
Concurrent controls, 198–199
Confidential Information, in trial site agreement, 45
Confidentiality of clinical studies, 4
in the research agreement, 42
Confidentiality Agreement, in clinical studies, 4
<table>
<thead>
<tr>
<th>Term</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous measurement scale</td>
<td>106</td>
</tr>
<tr>
<td>Contract financial considerations, for investigator-initiated clinical research</td>
<td>226–227</td>
</tr>
<tr>
<td>Contraindications, in CRFs</td>
<td>39</td>
</tr>
<tr>
<td>Control groups, examples of</td>
<td>198–200</td>
</tr>
<tr>
<td>Controlled clinical trials, composite endpoints for</td>
<td>100</td>
</tr>
<tr>
<td>Control population</td>
<td>198–200</td>
</tr>
<tr>
<td>Core laboratory selection</td>
<td>27</td>
</tr>
<tr>
<td>Corrective action, in interim monitoring visit report</td>
<td>75</td>
</tr>
<tr>
<td>Correlation</td>
<td>105</td>
</tr>
<tr>
<td>Correspondence</td>
<td>40</td>
</tr>
<tr>
<td>Cost-benefit analysis</td>
<td>109</td>
</tr>
<tr>
<td>Cost-effectiveness analysis</td>
<td>108</td>
</tr>
<tr>
<td>Cost-minimization analysis</td>
<td>108</td>
</tr>
<tr>
<td>Cost-utility analysis</td>
<td>109</td>
</tr>
<tr>
<td>CRF corrections, 30–32. See also Case report forms (CRFs)</td>
<td>30–32</td>
</tr>
<tr>
<td>CRF procedure</td>
<td>31</td>
</tr>
<tr>
<td>Crossover controls</td>
<td>199</td>
</tr>
<tr>
<td>Crossover trial design</td>
<td>201</td>
</tr>
<tr>
<td>Data in CRFs</td>
<td>30</td>
</tr>
<tr>
<td>de-identified data</td>
<td>177</td>
</tr>
<tr>
<td>examining across study centers</td>
<td>202</td>
</tr>
<tr>
<td>Data analysis, issues related to</td>
<td>202–206</td>
</tr>
<tr>
<td>Database cleaning</td>
<td>8</td>
</tr>
<tr>
<td>Database lock</td>
<td>7</td>
</tr>
<tr>
<td>Data collection management</td>
<td>25–26</td>
</tr>
<tr>
<td>in clinical protocol</td>
<td>20</td>
</tr>
<tr>
<td>Data correction forms (DCFs)</td>
<td>8</td>
</tr>
<tr>
<td>Data entry</td>
<td>7</td>
</tr>
<tr>
<td>Data examination, across study sites</td>
<td>124</td>
</tr>
<tr>
<td>Data management personnel</td>
<td>12</td>
</tr>
<tr>
<td>Data manager, in standard operating procedure</td>
<td>61</td>
</tr>
<tr>
<td>Data queries, generation of</td>
<td>8</td>
</tr>
<tr>
<td>Data Safety and Monitoring Board (DSMB)</td>
<td>168–170</td>
</tr>
<tr>
<td>adverse events and</td>
<td>82</td>
</tr>
<tr>
<td>bias minimization and</td>
<td>107</td>
</tr>
<tr>
<td>in medical device regulation</td>
<td>129</td>
</tr>
<tr>
<td>responsibilities of</td>
<td>169</td>
</tr>
<tr>
<td>setting up</td>
<td>168</td>
</tr>
<tr>
<td>Data Safety Monitoring Committee, 27</td>
<td>27</td>
</tr>
<tr>
<td>Declaration of Helsinki</td>
<td>xix, 231</td>
</tr>
<tr>
<td>Definitions, in standard operating procedure, 55, 56–57, 58–59, 61</td>
<td>61</td>
</tr>
<tr>
<td>De-identified data</td>
<td>177</td>
</tr>
<tr>
<td>Demographics, in CRFs</td>
<td>33</td>
</tr>
<tr>
<td>Design superiority, versus noninferiority</td>
<td>203</td>
</tr>
<tr>
<td>Device accountability</td>
<td>151</td>
</tr>
<tr>
<td>in final clinical study report</td>
<td>115</td>
</tr>
<tr>
<td>Device administration</td>
<td>151. See also Center for Devices and Radiological Health (CDRH)</td>
</tr>
<tr>
<td>Device approvals, in various world regions</td>
<td>152–153</td>
</tr>
<tr>
<td>Device description, in device investigational plan</td>
<td>155</td>
</tr>
<tr>
<td>Device development</td>
<td></td>
</tr>
<tr>
<td>FDA regulations related to</td>
<td>164–165</td>
</tr>
<tr>
<td>time and funds related to</td>
<td>144</td>
</tr>
<tr>
<td>versus drug development</td>
<td>143–154</td>
</tr>
<tr>
<td>Device Good Manufacturing Practice (GMP) Advisory Committee</td>
<td>138</td>
</tr>
<tr>
<td>Device Inventory Log</td>
<td>52, 54</td>
</tr>
<tr>
<td>Device legislation, key</td>
<td>129–130</td>
</tr>
<tr>
<td>Device malfunctions/issues/problems, in the final clinical study report</td>
<td>115, 118–119</td>
</tr>
<tr>
<td>Device regulations, 129–164</td>
<td></td>
</tr>
<tr>
<td>Device-related adverse events, analysis of</td>
<td>91</td>
</tr>
<tr>
<td>Device reporting, mandatory</td>
<td>92</td>
</tr>
<tr>
<td>Device risk classification</td>
<td>140–142</td>
</tr>
<tr>
<td>Devices. See also 510(K) entries; Medical device entries; Product codes</td>
<td></td>
</tr>
<tr>
<td>Class III, 159</td>
<td></td>
</tr>
<tr>
<td>classification of</td>
<td>132–133</td>
</tr>
<tr>
<td>in Code of Federal Regulations</td>
<td>194</td>
</tr>
<tr>
<td>defined, 143</td>
<td></td>
</tr>
<tr>
<td>description of</td>
<td>38</td>
</tr>
<tr>
<td>directions for use of</td>
<td>39</td>
</tr>
<tr>
<td>experimental, 141–142</td>
<td></td>
</tr>
<tr>
<td>indications and contraindications for</td>
<td>38–39</td>
</tr>
<tr>
<td>investigational product applications for</td>
<td>145</td>
</tr>
<tr>
<td>investigator monitoring related to</td>
<td>149</td>
</tr>
<tr>
<td>investigator responsibilities related to</td>
<td>150–151</td>
</tr>
</tbody>
</table>
Devices. (cont’d)
investigator selection related to, 148
marketing applications for, 147
mechanism of action of, 144
potential adverse events related to, 39
primary mode of action of, 164–165
regulation of, 145
reimbursement for, 153, 156–157
risk/benefit ratio of, 134
sponsor record retention related to, 150
sponsor reporting related to, 149–150
sponsor responsibilities related to, 148
storage and handling of, 39
unapproved, 159–162
Device studies, design issues in, 195–219
Device trials
global clinical studies and, 164
management issues in, 153
Device warnings, 39
Directions for use of devices, 39
Discrete measurement scale, 106
Diseases, risks associated with, 25
Documents
in clinical activity management, 10
development of, 15–62
required for clinical trial, xvii
Dos Santos, 176
Dosing studies, in animals, 167
Double blinding, bias minimization and, 107
Drug challenge issues, 151
Drug development
FDA regulations related to, 164–165
time and funds related to, 144
versus device development, 143–154
Drug/device administration, 151
Drug Eluting Stent (DES) study, design challenges of, 205–206
Drug regulation, versus medical device regulation, 158–159
Drugs
defined, 143
global clinical studies and, 163
investigational product applications for, 145
investigation monitoring related to, 149
investigator responsibilities related to, 150
investigator selection related to, 148
marketing applications for, 147
mechanism of action of, 144
primary mode of action of, 165
regulation of, 145
sponsor record retention related to, 150
sponsor reporting related to, 149
sponsor responsibilities related to, 148
Economic evaluations, 107–109
types of, 108–109
Efficacy endpoints, 98
Electronic CRFs, 29. See also Case report forms (CRFs)
Eligibility criteria, in clinical protocol, 22–23
Embryo, risks to, 36
Emergencies, unapproved medical devices used in, 159–160
Emergency use reviews, 182–183
Endarterectomy for Asymptomatic Carotid Artery Stenosis (ACAS) study, 216
Endpoint analysis, in the final clinical study report, 119
Endpoints, desirable features of, 98. See also Clinical study endpoints
Enrollment, in interim monitoring visit report, 75, 76
Equity interest, in financial disclosure certificate, 52
Equivalence hypothesis, 213–214
Ethical concerns, on use of placebo, 232–233
Ethical conduct
for human research, 229–233
principles of, 229–230
Europe
adverse-event reporting in, 88–89
device approvals in, 152
European Union (EU)
adverse-event reporting in, 88
global clinical studies and, 163
Event-product relationship, in reporting SAEs, 86
Exclusion criteria, in CRFs, 33
Executive summary, in the final clinical study report, 114, 116–117
Exempt reviews, 189
Exhibits, study-related, 39–40
Expedited reviews, 188
IRB, 182
of IRB noncompliance issues, 189
Experimental devices, 141–142
Experimental procedures, in clinical protocol, 17, 23–26
Facilities, evaluation of, 66
Facility review, in interim monitoring visit report, 75, 76
Factorial trial design, 201
FDA (Food and Drug Administration) acceptance of foreign clinical studies, 162
in adverse-event reporting, 89
in adverse-event reporting in postmarket studies, 91
adverse events and, 82
agreement concerning objective performance criteria, 208
Bayesian statistics guidelines from, 109
combination products and, 164
common deficiencies cited by, 193–194
compassionate unapproved device use and, 160–162
device investigational plans and, 155–156
emergency unapproved device use and, 160
510(K) process and, 133–136
in global clinical studies, 18
HDE and, 132
IDE and, 131–132
and investigator and staff review, 66
IRB coordinator and, 13
and IRB procedures, 182–189
and IRB structure and function, 181
in mandatory device reporting, 92
in medical device regulation, 129–130
oversight of clinical trials, 191–194
records inspection by, 151
sponsor reporting to, 149–150
in standard operating procedure, 57
statistical analysis plan and, 94
in trial site agreement, 44, 46
type I/II errors and, 102
use of historic controls and, 206
FDA acceptance of a clinical study, xviii
FDA advisory panels, 138
roles and functions of, 138–139
FDA Annual Progress Report Outline, template of, 8–9
FDA approval, 5, 6, 165–166
FDA-approved devices, mandatory device reporting for, 92
FDA audit, preparation for, 193–194
fda.gov/oc/combination, 168
FDA meetings, preparation for, 173–174
FDA organizational structure, 130–131
FDA panel discussion, 215
FDA regulations, xv, xvi, xviii
for combination products, 164–165
in device versus drug development, 164–165
and IRB procedures, 182–189
and IRB structure and function, 181
See also Sponsor(s) minutes of, 174
FDA standards, type I/II errors and, 102
Feasibility studies, 159, 197
Federal Food, Drug, and Cosmetic Act, IRB procedures and, 181
Federal Food, Drug, and Cosmetic Act, IRB procedures and, 185
Federal wide assurance (FWA), 26
Fetus, risks to, 36
Final clinical study report, 113–125
development of, 8
outline of, 114–116
sections in, 116–125
Financial budgets, for investigator-initiated clinical research, 226
Financial disclosure certificate, 51–52
First patient in, 7
Fisher’s exact test, 105
510(K), premarket notification using, xviii. See also Premarket notifications [510(K)]
510(K) postmarket issues, 136
510(K) Premarket Notification-Practical Points, 133
510(K) Premarket Notification Substantial Equivalence, 133
510(K) process, summary of, 133–136
510(K) Requirements, 134
510(K) “Substantial Equivalence” decision-making process, 134–136
Follow-up CRFs, 31
Follow-up visits, in clinical protocol, 17
Food and Drug Administration (FDA). See FDA entries
Food and Drug Administration Modernization Act of 1997 (FDAMA), 130
Foreign clinical studies, FDA acceptance of, 162
Foreseeable risks, 25
Full reviews, 188
Future plans, in FDA Annual Progress Report, 9
Global clinical studies, 162–164
CRFs for, 29
protocol development for, 18
Global Medical Device Nomenclature (GMDN) codes, 137
Glossary, xix
GMDN device categories, 137
Good clinical practices (GCP), xvi, 6
ICH, 157–158
Good manufacturing practices (GMP),
good clinical practice and, 158
Guidance documents, 130
Guidelines, regarding adverse-event reporting, 84
Hard endpoints, 98
Health economic outcomes, defining, 107
Health information, protected, 175–178
Health Insurance Portability and Accountability Act of 1996 (HIPAA), 175. See also HIPAA entries
application to research, 176
HIPAA privacy rule, xviii
implementation in clinical research, 175–180
interim monitoring visit report and, 79
interim monitoring visits and, 71
in trial site agreement, 45–46
HIPAA privacy standards, compliance with, 175
HIPAA rules, in medical device regulation, 129
Historical Control ICAI Study, 211
Historic control assumptions, 216
Historic(al) controls, 199
in the ARCHeR trial, 217
best-case, 211
clinical studies with, 209–217
defined, 207
justification for selecting, 210–211
recommendations when using, 218–219
use in IDE studies, 206–217
Humanitarian Device Exemption (HDE), xviii, 132
in financial disclosure certificate, 51
in medical device regulation, 129
Humanitarian use device (HUD), 132
Human research, ethical conduct for, 229–233
Hypotheses
a priori and a posteriori, 106
power of, 102
testing, 101
ICAI Study, 211
ICF requirements, exceptions from, 38.
See also Informed consent form (ICF)
ICH good clinical practice (GCP),
principles of, 157–158. See also International Conference on Harmonization (ICH) guidelines
ICH regulations, xv
IDE amendments, 131–132. See also Investigational Device Exemption (IDE)
IDE approval/disapproval, 142–143
IDE conditional approval, 142
IDE decision process, 146
IDE deliverables, 154
IDE exemptions, 146
IDE holder, emergency unapproved device use and, 160
IDE studies
statistical analysis plan and, 94
use of historic controls in, 206–217
IDE supplements, 131–132
compassionate unapproved device use and, 160–162
Illiterate persons, IRB procedures and, 185–186
<table>
<thead>
<tr>
<th>Index Entry</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inclusion criteria, in CRFs</td>
<td>33</td>
</tr>
<tr>
<td>IND application</td>
<td>146–147. See also Investigational new drug (IND)</td>
</tr>
<tr>
<td>Indemnification</td>
<td>43</td>
</tr>
<tr>
<td>Indemnification research contract challenge</td>
<td>50–51</td>
</tr>
<tr>
<td>Independent ethics committee (IEC), in good clinical practice</td>
<td>157</td>
</tr>
<tr>
<td>IND exemptions</td>
<td>145–146</td>
</tr>
<tr>
<td>Indications, in CRFs</td>
<td>38</td>
</tr>
<tr>
<td>Industry, risks associated with</td>
<td>224</td>
</tr>
<tr>
<td>Influencing variables</td>
<td>197–198</td>
</tr>
<tr>
<td>Information resources, for combination products</td>
<td>168</td>
</tr>
<tr>
<td>Informed consent (IC), 180, 184–186 monitoring, 37 obtaining, 151 problems with</td>
<td>189–190</td>
</tr>
<tr>
<td>Informed consent and authorization interim monitoring visit report and, 79 interim monitoring visits and, 71 in trial site agreement, 46</td>
<td></td>
</tr>
<tr>
<td>Informed consent document, contents of</td>
<td>186–187</td>
</tr>
<tr>
<td>Informed consent form (ICF), xvii, 5, 16, 35–38. See also ICF requirements elements of, 35–36 emergency unapproved device use and, 160 IRB/EC approval of, 5 template for, 28</td>
<td></td>
</tr>
<tr>
<td>Infrastructure, for investigator-initiated clinical research</td>
<td>226–227</td>
</tr>
<tr>
<td>Initial/continuing reviews, of IRB noncompliance issues</td>
<td>189</td>
</tr>
<tr>
<td>Initiation visit report</td>
<td>73–74</td>
</tr>
<tr>
<td>Inspection of clinical investigators, 191–192 of study sponsors, 193</td>
<td></td>
</tr>
<tr>
<td>Institutional Review Board/Ethics Committee (IRB/EC), xvi, 26–27 approval of protocol, informed consent form, and advertising materials, 5 in interim monitoring visit report, 78, 79 interim monitoring visits and, 71 and investigator and staff review, 66 Institutional Review Boards (IRBs), 5, 6, 180–189. See also IRB entries adverse-event reporting and, 85 emergency unapproved device use and, 160 functions of, xviii in good clinical practice, 157 interim monitoring visits and, 71 investigator/sponsor communication with, 183 involvement with humanitarian device exemptions, 132 monitor duties and, 69 protocol deviations/violations and, 122 and responsibilities of Principal Investigator, 65 review and approval of clinical investigations, 187 reviews conducted by, 188–189 structure and function of, 180–188 in trial site agreement, 44 Institutions risks associated with, 224 in trial site agreement, 44–45, 47–48, 48–49 Instructions for use (IFU), xvii Instructions for Use of Device document, 38–39 Insurance research contract challenge, 50, 51 Integrity in clinical protocol, 17–18 ensuring, 26–28 Intellectual property rights, 42–43 for investigators, 223 Intended Use protocol section, 19, 21–22 Interim Monitoring Visit Report(s), 73, 74 interim monitoring visits and, 72 sample of, 74–75 template for, 75–80 Interim monitoring visits, 70–72 Interim visit findings, in interim monitoring visit report, 80 Interim visits, in monitoring plan, 69–70 International Conference on Harmonization (ICH) guidelines, 84. See also ICH entries International regulations, xvi</td>
<td></td>
</tr>
</tbody>
</table>
Intervention methods of assigning, 200
in protocol development process, 18
Investigational device accountability, in final clinical study report, 115, 118
Investigational Device Exemption (IDE), xviii, 5, 131–132, 145. See also IDE entries; Pre-IDE/IND entries in adverse-event reporting, 89 clinical deliverables in, 155–156 in financial disclosure certificate, 51 global clinical studies and, 163 IRB procedures and, 186 in medical device regulation, 129
Investigational new drug (IND), 145. See also IND entries
Investigational plan, 154 components of, 155–156
Investigational product (IP), in interim monitoring visit report, 77
Investigational product applications, for drugs and devices, 145
Investigation monitoring, drug- and device-related, 149
Investigator and staff review, in Qualification Visit Questionnaire, 65
Investigator brochure, 154
Investigator responsibilities, drug- and device-related, 150–151
Investigators communication with IRB, 183 intellectual property rights for, 223 interim monitoring visits and, 71 potential, 67 qualification/selection of, 4, 64–67 risks associated with, 224 selection of, 26 subject injury and, 223
Investigator selection, 4, 64–67 drug- and device-related, 148
Investigator/site qualification visit, 70
Investigator-sponsored clinical trials, xix
IRB activities, problems with documentation of, 190–191. See also Institutional Review Boards (IRBs) IRB coordinator, 13
IRB inspections, 183–184
IRB membership, problems with, 190
IRB noncompliance issues, 189
IRB procedures, 182–189
IRB records, 184
IRB review, of protocol changes, 189–191
IRB roster, 181
IRB waiver criteria, 176
Japan, device approvals in, 152–153
Kaplan–Meier survival curves, 111–112
Key clinical deliverables, 2–3
Key clinical tasks/activities, management of, 9–10, 11
Key information resources, for combination products, 168
Knowledge, in changing clinical-trial primary outcome, 101
Labeling, in device investigational plan, 155
LACI clinical study, 209–211 design of, 213 outcomes from, 214
LACI Phase 2 Registry results, 212–213
Laser angioplasty for critical limb ischemia (LACI), TASC types in, 212. See also LACI entries
Last patient out, 7
Laws, 130. See also Legislation Legislation, device, 129–130
Letter of intent (LOI), 225
Limited data sets (LDS), 177–178
Lipid-lowering agents study, surrogate endpoints and, 99
Local effects, 109
Local IRBs, 180
Long-term adverse events, analysis of, 91
Losartan Trial, 204–205
Maintenance, of devices, 39
Major adverse coronary event (MACE), 205. See also Myocardial infarction (MI)
Management
of clinical tasks/activities, 2
of investigator-initiated clinical research, 224–225, 226
of key clinical tasks/activities, 9–10, 11
Mandatory device reporting, for FDA-approved devices, 92
Market, regulatory pathways to, 133–134
Marketing applications, of drugs and devices, 147
Masking, 202
Measurements, repeated, 203
Measurement scales, 106. See also Units of measurement
Medical Device Advisory Committee, 138
Medical Device Amendment of 1976, 129
Medical device regulation(s), 129–164 versus drug regulation, 158–159
Medical devices. See also Device entries classification of, 132–133
in Code of Federal Regulations, 194
unapproved, 159–162
Medical device studies, design issues in, 195–219
Medical Device User Fee and Modernization Act of 2002, 130
Medical history, in final clinical study report, 115
Medical records, 36
Medication, randomizing versus, 210
Medication(s) Used, in CRFs, 34
Meetings
DSMB, 169
FDA-sponsor, 170–174
Meta-analysis studies, 110–111
Methodology and procedures summary, in the final clinical study report, 117
Mild adverse events, 88
Minimal risk studies, 141
Ministry of Health, Labor and Welfare (MHLW), Japan, device approvals by, 152–153
Missing data
avoidance of, 122
handling, 121–122
imputation of, 121–122
Missing data analysis, in the final clinical study report, 116, 121
Moderate adverse events, 88
Modular PMA submission, 139
Monitor(s)
duties of, 68–69
interim monitoring visits and, 71
responsibilities of, 68
in standard operating procedure, 56, 58
Monitoring plan, 27, 69–70
monitoring visits for, 67–68
Monitoring procedures, 27
in device investigational plan, 155
Monitoring reports, 73–75
types of, 73
Monitoring visits, 67–73
scheduling, 67–68, 69–70
Monitor selection, drug- and device-related, 149
Monitor(ing) Visit Log, 52, 53
interim monitoring visits and, 71
Most Probable cause-effect relationship, 85
Multivariate analysis, 124
Myocardial infarction (MI), optimal trial in, 204–205. See also Acute myocardial infarction (AMI)
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 231
National Institutes of Health. See NIH-sponsored clinical research
National Mammography Quality Assurance Advisory Committee, 138
National Research Act of 1974, 231
New drug application (NDA), 182
NIH-sponsored clinical research, 227
95% confidence intervals, 105
No Action Indicated compliance classification, 192
Nonexperimental devices, 142
Noninferiority trials, 203–204
Nonsignificant risk (NSR) devices, determination of, 140–141
Nonsignificant risk studies, 141
North American Symptomatic Carotid Endarterectomy Trial (NASCET), 216
Not Related cause-effect relationship, 85
Null hypothesis, 102, 103
Number needed to treat (NNT), 108
Nuremberg Code, 230–231

Objective Performance Criteria (OPC), 207–208
determining, 208
FDA agreement concerning, 208
Office for Human Research Protections (OHRP), 189–191
Official Action Indicated compliance classification, 192
On-site visits, record of, 73
“Optimal” trials, 204–205
Outcome, recording adverse-event, 87
Outcome variables, 197

Parallel trial design, 200
Parameter estimates, 95% confidence intervals for, 105
Passive concurrent controls, 199
Patient disposal/accountability, 117
Patient enrollment, in the final clinical study report, 114, 117
Patient population, in clinical studies, 66–67, 121

Patient recruitment
in clinical protocol, 4
in clinical studies, 66–67
Patients’ baseline characteristics analysis of, 117–118
in final clinical study report, 114–115
Patient Screening Log, 52–53
Patient selection criteria, in clinical protocol, 4
Payments, in financial disclosure certificate, 52
Pharmacokinetic (PK) testing, 167
Phase I studies, 158, 159
Phase II studies, 158–159
Phase III studies, 159
Phase IV studies, 159
Physical Exam, in CRFs, 34
Pilot studies, 159, 197
Pivotal clinical study, 2
Pivotal trials, 159
FDA meetings prior to initiating, 172
Placebo, ethical concerns related to, 232–233
Planned emergency research, exception from ICF for, 38
PMA postmarket issues, 139. See also Pre-Market Approval (PMA)
PMA studies, data analysis of, xviii
PMA submission, 139–140
FDA response time to, 140
Policies, regarding adverse-event reporting, 84
Population selection criteria in clinical protocol, 17, 21
for study and control populations, 198–200
Possible cause-effect relationship, 85
Postmarket issues, PMA, 139
Postmarket studies, 159
adverse-event reporting in, 91
Potential adverse events, in standard operating procedure, 59, 60
Potential investigators, communication with, 67
Potential risk perspective, 223–224
Power of a hypothesis, 102. See also Statistical power in sample-size calculation, 103, 104
Preclinical phase, FDA meetings during, 171–172
Pre-IDE/IND meeting, 166. See also Investigational Device Exemption (IDE); Investigational new drug (IND); Pre-IDE meetings/teleconferences
Pre-IDE/IND submission, 166
Pre-IDE meetings/teleconferences, xviii, 171–172
informal, 173
Pre-Market Approval (PMA), 131
in financial disclosure certificate, 51
in medical device regulation, 129
summary of, 139–140
Premarket Approval Application, xviii, 134
in trial site agreement, 46
Premarket Approval Application—Practical Points, 134
Pre-Market Notification, in financial disclosure certificate, 51
Premarket notifications [510(K)], 131. See also 510(K)
Premarket phase, FDA meetings during, 171
Primary effectiveness (efficacy) endpoints, 98
Primary endpoint, limitations to analysis of, 214
Primary Investigators, in trial site agreement, 44–45, 47–48, 48–49. See also Principal Investigator (PI)
Primary mode of action, 164–165
Primary outcome, 106 changing, 101
Principal Investigator (PI)
in clinical studies, 4
in interim monitoring visit report, 74, 77
monitor duties and, 69
in research contract, 6
responsibilities of, 64–65
in standard operating procedure, 56, 58
study close-out visit and, 72
Principal investigator (PI) and site qualification report, 73
Printed CRFs, 29, 30
Prior investigations report, 155
Privacy Rule, in trial site agreement, 45–46
Probability, Bayes’s theorem in, 109
Problems
in compassionate unapproved device use, 161–162
unanticipated, 189–191
Procedure-related adverse events, analysis of, 91
Procedures manual, xvii
Product codes, 136–138
Product-event relationship, in reporting SAEs, 86
Progress reports, 8–9
Projected clinical outcome, in clinical protocol, 21
Project timeline, in investigator-initiated clinical research, 225

Proof of concept, FDA meetings prior to, 171
Proprietary interest, in financial disclosure certificate, 52
Protected health information (PHI), 175–178
allowable conditions for use in research, 176–180
authorization of use of, 176–177, 178–179
defined, 177
preparatory to research, 179
Protocol
approval of, 5
data and, 7–8
in device investigational plan, 155
global clinical studies and, 163–164
in investigator-initiated clinical research, 222
IRB/EC approval of, 5
Protocol changes, IRB review of, 189–191
Protocol development process, 17–18
for global clinical studies, 18
Protocol Deviations protocol section, 28
Protocol deviations/violations, in the final clinical study report, 122–123
Protocol draft, in protocol development process, 17
Protocol information, in interim monitoring visit report, 74
Protocol review, 17
Protocol summary, 3, 17
in protocol development process, 17–18
Protocol synopsis, 2, 3, 17
in final clinical study report, 114
in protocol development process, 17–18
Protocol Violations Report, 122–123
PTA (percutaneous transluminal angioplasty), randomizing versus, 211
Publication, of investigator-initiated clinical research, 223
Publication Policy research contract challenge, 50, 51
Publication rights, in the research agreement, 42
Purpose
in clinical protocol, 17, 19
in device investigational plan, 155
of standard operating procedure, 54, 55, 58, 61
$P$ value, 105

Qualification Visit Questionnaire, 64, 65–66
Quality assurance, 25–26
Quality control, in clinical protocol, 17–18, 20

Randomization, 26
bias minimization and, 107
justification for selecting, 210–211
Randomized clinical studies, IDE and, 206
Randomized controlled clinical trials, composite endpoints for, 100
Rationale, for standard operating procedure, 55
RCT (randomized control trial), use in IDE studies, 206. See also Randomized controlled clinical trials
Record keeping, in trial site agreement, 46
Record of On-site Visits, 73
Record Retention protocol section, 28
Records inspection, FDA, 151
Recruitment questions/practices, protected health information and, 179

References
citing, 28
for standard operating procedure, 55, 57, 61, 62
Registration requirements, for investigator-initiated clinical research, 223
Regression, 105
Regression. See also Regulations of drugs versus devices, 145
of investigator-initiated clinical research, 225–226
Regulations, 130. See also Regulation medical device, 129–164
regarding adverse-event reporting, 84
Regulatory documents, types of, 130
Regulatory follow-up, of BIMO audit outcome, 193
Regulatory obligations, of sponsors, 192
Regulatory pathways to market, 133–134
Regulatory review, in interim monitoring visit report, 75, 78
Regulatory specialist, 13
Reimbursement, for newly approved devices, 156–157
Relative risk reduction (RRR), 108
Reports, prior investigations, 155
Research
conditions for use of PHI in, 176–180
HIPAA application to, 176
protected health information and, 179
Research agreement, 40–43
confidentiality in, 42
exhibits and amendments in, 42
provisions of, 41
publication rights in, 42
template for, 43–50
Research contracts, 5–6
challenges to, 50–51
exhibits and amendments in, 42
genereal provisions of, 41
miscellaneous provisions of, 41
special provisions of, 41
structure of, 40–42
Research personnel information, 40
Research question/hypothesis, 18–19, 196–197
Research records, subject access to, 179–180
Research staff members, in protocol development, 3
Research team
clinical, 10–13
in protocol development process, 17
Resources, in investigator-initiated clinical research, 223
Responsibilities of Principal Investigator, 64–65
in standard operating procedure, 55, 57, 59, 62
Reviews adverse events and, 82
protocol, 17
RevMan tests, 105
Risk analysis. See also Potential risk perspective
  in clinical protocol, 20
  in device investigational plan, 155
  in FDA Annual Progress Report,
Risk/Benefit Analysis protocol section,
25
Risk/benefit ratio, of a device, 134
Risk minimization, in protocol
development process, 19
Risk reduction, 108
Risk review, IRB, 182
Risks
  from adverse events, 60
  device-related, 39
  embryo or fetus, 36
RXACCULINK™ Carotid Stent System, 215
Safe Medical Devices Act of 1990,
129–130
Safety endpoint, 205–206
Safety evaluations, in the final clinical study report, 116, 119–120
Sample size, 202
  in clinical protocol, 20
Sample size calculation, 103, 104
  in clinical protocol, 4
Sample Size Determination/Statistical Analysis protocol section, 24
Scheduled visits, in monitoring plan,
69–70
Schedule of assessments, in clinical protocol, 23–24
Scope, of standard operating procedure,
54, 55, 58, 61
Screening/enrollment case report form,
32–34
Screening Log, 52–53
Secondary endpoints, 98
Secondary hypothesis, 106
Self-controls, 199
Serious adverse event narratives, 89–90
Serious adverse events (SAEs), 83, 88
definitions of, 86
monitor duties and, 68
reporting, 88
  in standard operating procedure, 59, 60
Serious adverse events/adverse events (SAE/AE), versus unanticipated adverse device effects, 153
Severity, recording adverse-event, 87
Significant risk (SR) devices, 140
Simulated trials, Bayesian statistics in,
110
Site Communications Log, 52
Site Delegation of Authority Log, 52, 53
Site investigators, adverse-event reporting challenges of, 86
Site qualification report, 73
Site qualification visit, 70
Site staff, in interim monitoring visit report, 75, 77
Site Training Log, 52, 53–54
Slow enrollment, in clinical studies,
66–67
Soft endpoints, 99
SOP Attachments section, 57, 61, 62. See also Standard operating procedures (SOPs)
SOP contents, 54–55
SOP Definitions section, 56–57, 58–59, 61
SOP Procedures section, 57, 60, 62
SOP Purpose section, 55, 58, 61
SOP References section, 57, 61, 62
SOP Responsibilities section, 57, 59, 62
SOP Scope section, 55, 58, 61
Source documentation, in interim monitoring visit report, 79
Source documents, 32
  interim monitoring visits and, 71
Special device issues, 151
Sponsor(s). See also FDA-sponsor meetings; Study sponsors and adverse-event reporting, 86–87, 88, 92
  in clinical studies, 4
  communication with IRB, 183
FDA and, 5
  of foreign clinical trials, 162
  indemnification by, 43
  in interim monitoring visit report, 75
IRB procedures and, 185, 186
Sponsor(s). (cont’d)
protocol deviations/violations and, 122
qualification/selection of investigators
and, 64
regulatory obligations of, 192
and responsibilities of Principal
Investigator, 65
right of inspection of, 46
study close-out visit and, 72
study initiation visit and, 70
study research contract and, 5–6
study visits by, xvii
in trial site agreement, 45, 47–48,
48–49, 50
Sponsor record retention, drug- and
device-related, 150
Sponsor reporting, drug- and device-
related, 149
Sponsor representative, in clinical
studies, 4
Spread sheets, for clinical study activity
management, 10, 11
Staff review, in Qualification Visit
Questionnaire, 65
Standardization, bias minimization and,
107
Standard operating procedures (SOPs),
xvi, xvii, 16, 54–62. See also SOP
entries
monitor duties and, 68–69
rationale for developing, 55
Statistical analysis, in clinical protocol,
20
Statistical analysis plan (SAP), xvii, xviii,
8, 12, 94–101
adverse events and, 82
outline of, 95–96
overview and contents of, 94–95
requirements for, 97
in standard operating procedure, 61, 62
Statistical methods, in clinical protocol,
17
Statistical power, 202. See also Power of
a hypothesis
of a study, 121
Statistical procedures, basis for
justification of, 104–105
Statistical significance, 105
Statistical significance difference, 105
Statistician, in standard operating
procedure, 62
Statistic procedures, xviii
Steering committees, 27, 170
setting up, 168
Storage, of devices, 39
Stratification, 201
Streamlined PMA submission, 140
Student’s t-test, 104
Studies. See also Clinical study entries;
Research entries
changing the primary outcome during,
101
FDA approval for, 5
safety and effectiveness outcome of,
xvii
submission to a second IRB, 183
Study background, in clinical protocol,
19, 21
Study case report forms (CRFs), 26,
28. See also Case report forms
(CRFs)
Study centers
examination of data across, 202
in the final clinical study report, 114,
117
Study clinical materials, 40
Study clinical protocol, 2
Study close-out, 7
Study close-out report, 73, 74
Study close-out visit, 72
in monitoring plan, 70
Study committees, 27, 168–170
in clinical protocol, 4
Study compliance analysis, in the final
clinical study report, 116, 120–121
Study contracts, 153
Study correspondence, 40
Study Design protocol section, 19–20,
22–23
Study designs
in clinical protocol, 19–20, 22–23
differences in, 147–148
Study device, adverse events and, 87
Study endpoint analysis, in the final
clinical study report, 119
Study endpoints
in clinical protocol, 17, 22
selecting, 97–101
Study experimental procedures, in clinical protocol, 23–26
Study findings, in interim monitoring visit report, 75, 80
Study groups, parameters used to compare, 106
Study hypothesis, 101
  example of, 103–104
Study initiation visit, 6–7, 70
Study interpretation/conclusions, in the final clinical study report, 124–125
Study investigators, 202
  qualification/selection of, xvii, 64–67
Study manager, 11–12
Study materials, development of, 3–4
Study monitor(s), xvii
  duties of, 68–69
  in monitoring plan, 69
  responsibilities of, 68
Study objectives, in final clinical study report, 115
Study outcome, 106
  effect of missing data on, 121
  in protocol development process, 18
Study participants, in protocol development process, 18
Study population, 198
Study procedure, adverse events and, 87
Study progress, in FDA Annual Progress Report, 9
Study progress reports, 8–9
Study protocol, adverse-event reporting in, 85
Study Purpose protocol section, 17, 19, 21
Study quality assurance, 25–26
Study randomization/blindness, 26
Study rationale, in clinical protocol, 19, 21
Study regulatory binder, 16
Study regulatory binder file, 39–40
Study Reports protocol section, 28
Study research agreement, 40–43. See also Research agreement
Study research contract, 5–6
Study safety evaluation, in the final clinical study report, 119–120
Study sites, 202
  examination of data across, 124
  selection of, xvii
Study sponsors. See also Sponsor(s)
  FDA meetings with, 170–171
  inspection of, 193
Study statistician, in standard operating procedure, 62
Study tracking logs, 40
Study visits, xvii
  types of, 70–72
Sub-activity tasks, 2
Subgroup analysis, 203
  in the final clinical study report, 116, 123–124
Sub-Investigator (Sub-I), in standard operating procedure, 56
Subject accrual, in interim monitoring visit report, 76
Subject Identification Code List, 30
Subject individual data sets, in the final clinical study report, 120
Subject injury, 223
Subjects
  access to research records, 179–180
  informed consent of, 184–186
  in standard operating procedure, 57, 58
Subject’s Injury research contract challenge, 50, 51
“Substantial Equivalence” decision-making process, 134–136
Superiority trials, 203–205
Surrogate endpoints, 99
  composite endpoints and, 100
Synchronization, in global clinical studies, 18
Systemic effects, 109
System Organ Class (SOC)-Body adverse event classification system, 90–91
TASC (TransAtlantic Inter-Societal Consensus), 211–212
Technical Electronic Product Radiation Safety Standard Committee, 138
Test articles, emergency use review of, 182–183
Theoretical risks, 25
Time frame, for reporting SAEs, 86
Time onset, recording adverse-event, 87
Toxicity testing, 167
Tracking logs, 40
Traditional PMA submission, 140
Treatment
  in changing clinical-trial primary outcome, 101t
  in protocol development process, 18
Treatment IND/IDE, 187–188
Trial data, quality and integrity of, xvii
Trial design(s), 167–168
  blocking or stratification in, 201
  specific, 200–201
Trial objective, 196–197
Trial quality/integrity, ensuring, 26–28
Trial results-confounders, 111
Trial site agreement, 43–50
  Individually Identifiable Health Information provision, 45–46
  Intellectual Property provision, 48–49
  Liability/Insurance/Warranty
    Disclaimer provision, 47
  miscellaneous provisions, 49
  parties to, 44
  Performance of the Trial provision, 44–45
Record Keeping/Retention provision, 46
Sponsor’s Right of Inspection provision, 46
Termination of Agreement or
  Termination of a Party’s Participation in Agreement provision, 48
Use of Name/Publicity/Scientific Publications provision, 47–48

<table>
<thead>
<tr>
<th>Unanticipated adverse device effects (UADEs), 83, 150</th>
</tr>
</thead>
<tbody>
<tr>
<td>defined, 88</td>
</tr>
<tr>
<td>reporting, 88</td>
</tr>
<tr>
<td>in standard operating procedure, 59, 60</td>
</tr>
<tr>
<td>versus serious adverse events/adverse events, 153</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Unanticipated adverse events, recording, 87</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unanticipated problems, reporting, 189–191</th>
</tr>
</thead>
</table>

| Unapproved medical devices
  compassionate use of, 160–162                           |
| emergency use of, 159–160                                |

<table>
<thead>
<tr>
<th>Unexpected events, determining, 87</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>United States (US). See also FDA entries; National entries adverse-event reporting in, 88–89</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>global clinical studies and, 18, 163–164</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>medical device regulation in, 129</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Units of measurement, global clinical studies and, 163–164. See also Measurement scales</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unlikely cause-effect relationship, 85</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Variables, identification and selection of, 197–198</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Variance, in sample-size calculation, 103</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Verification of Subject Eligibility, in CRFs, 34</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Voluntary Action Indicated compliance classification, 192</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Voluntary participation, 36</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Waiver of authorization requirement, 178–179</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>World Health Organization (WHO), adverse event classification by, 90–91</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>World Medical Association, 231</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>World regions, device approvals in, 152–153</th>
</tr>
</thead>
</table>